SPARC announces positive results from Phase 3 trial of PDP-716
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day
The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
The facility is expected to be completed in 2024
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5% has an estimated market size of US $80 million for twelve months ending December 2020 according to IQVIA
The company reported total income of Rs.390.05 crores during the 12 months period ended March 31, 2021
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Subscribe To Our Newsletter & Stay Updated